Market ExpansionProspects of Afrezza in additional patient populations suggest potential market expansion.
Revenue GrowthStrong Tyvaso DPI revenue growth was reported by MannKind's partner, United Therapeutics, indicating robust performance and potential for continued growth.
Royalty RevenueMannKind Corporation will be eligible for royalties from Tyvaso DPI revenue in IPF, which is considered as an upside potential.